Tessa Therapeutics, a Singapore-based international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, completed a $80m financing round.
The round was led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.
The company intends to use the proceeds from this funding round to further advance its clinical pipeline and to bring new therapies, based its Virus Specific T cell (VST) platform, into clinical trials.
Led by Andrew Khoo, co-founder and CEO, Tessa Therapeutics is currently conducting a multi-center Phase III trial targeting nasopharyngeal cancer and a Phase I trial targeting cervical cancer and oropharyngeal cancer.
Virus-Specific T cells are produced through a selective expansion process that gives them the ability to infiltrate and survive in solid tumors long enough to attack and destroy them from within, a key differentiator to other cell therapies. Tessa’s VSTs migrate to the tumor site and kill cancer cells leaving healthy cells unharmed, leading to treatment efficacy and safety.